GLP-1 Risk Assessment Calculator: Evaluate Safety, Side Effects, and Metabolic Risk
Understand your potential risk profile before starting or adjusting a GLP-1 agonist. This calculator analyzes key factors like body composition, dosing range, metabolic markers, and known side effect patterns to give you a clearer picture of how compounds like semaglutide, tirzepatide, and others may impact your system. Use it to make more informed, data-driven decisions instead of guessing.
Important Disclaimer: This calculator is for educational and research purposes only. It does not replace clinical judgment or individual assessment. Consult appropriate clinical guidelines and specialist evaluation for individual care decisions.
What This Calculator Evaluates
Eligibility & Contraindication Screening
The assessment begins with your baseline metrics and checks for hard-stop contraindications such as medullary thyroid carcinoma history or MEN2 syndrome. It also flags major cautions including pregnancy status, pancreatitis history, gallbladder disease, gastroparesis, and kidney function each with context explaining why it matters.
The assessment also considers special population factors where applicable, including pregnancy status, breastfeeding, age-related risk, and existing chronic disease conditions that may alter risk thresholds.
Medication-Specific Risk Profiling
Select from current GLP-1 agents including semaglutide, tirzepatide, and others. The tool adjusts risk calculations based on your chosen medication, target indication, and planned treatment duration. Biliary event risk differs significantly between weight loss and diabetes indications — the calculator accounts for this.
Dietary and Weight Loss Pattern Analysis
Rapid weight loss is one of the strongest modifiable risk factors for biliary complications during GLP-1 therapy. The assessment evaluates your weekly weight loss rate, total weight loss trajectory, and dietary approach — from very low fat to ketogenic to intermittent fasting — each carrying a different risk profile for gallbladder-related events.
Rapid weight loss is one of the strongest modifiable risk factors for biliary complications during GLP-1 therapy. The assessment evaluates your weekly weight loss rate, total weight loss trajectory, and dietary approach.
This includes analysis of macronutrient composition, caloric intake, and food quality, ranging from very low-fat to ketogenic to intermittent fasting strategies. Each carries a different impact on fat metabolism, gallbladder function, and overall metabolic stress.
Nutritional patterns also influence cholesterol balance, glucose control, and energy availability, which can affect both short-term tolerance and long-term outcomes.
Clinical Risk Factor Scoring
Ten additional clinical risk factors are evaluated and weighted, including age, sex, prior gallstone history, triglyceride levels, liver disease (MASLD/NASH), kidney function, tobacco use, and diabetes status.
This model also incorporates broader cardiovascular and metabolic indicators such as blood pressure, hypertension status, lipid markers including LDL, and overall vascular health, all of which contribute to stroke and heart disease risk.
Lifestyle variables are included where they directly influence outcomes, including nutrition quality, sodium intake, hydration, physical activity level, and body weight trends. These factors help contextualize how rapidly changing physiology during GLP-1 use may affect stability.
Each factor contributes to your overall risk score with explanations grounded in clinical research, allowing for structured risk management rather than isolated interpretation.
What This GLP-1 Risk Calculator Actually Evaluates
This GLP-1 risk assessment calculator is designed to evaluate how multiple variables interact, not just a single input like weight or dosage. Risk is rarely isolated. It is the result of overlapping factors including cardiovascular health, metabolic condition, nutrition, and lifestyle patterns.
Rather than treating GLP-1 use as a standalone variable, this tool analyzes how different inputs combine to influence overall risk exposure.
Cardiovascular Disease and Stroke Risk
Cardiovascular disease remains one of the most important considerations when evaluating GLP-1 use. Individuals with a history of heart disease, stroke, or vascular issues may experience different responses depending on how rapidly metabolic changes occur.
Blood pressure shifts, lipid changes, and fluid balance can all influence cardiovascular stability. Stroke risk is closely tied to these same variables, particularly in individuals with hypertension or arterial stiffness.
This calculator incorporates these factors to help identify elevated cardiovascular risk patterns.
Blood Pressure, Sodium, and Circulatory Stability
GLP-1 compounds can influence appetite and fluid intake, which indirectly affects sodium levels and blood pressure regulation. Reduced sodium intake combined with lower hydration can lead to dizziness, fatigue, or unstable blood pressure.
For individuals managing hypertension, these shifts may either improve or destabilize control depending on lifestyle and intake patterns.
This tool evaluates how these inputs contribute to overall circulatory stability.
Cholesterol, LDL, and Lipid Metabolism
Lipid metabolism plays a central role in long-term risk assessment. While GLP-1 use is often associated with improved lipid profiles, transitional changes can occur during active weight loss.
Elevated low-density lipoprotein (LDL), changes in fat metabolism, and dietary patterns all influence cardiovascular outcomes.
This calculator includes lipid-related inputs to provide a more complete metabolic risk profile.
Kidney Function and Hydration Risk
Kidney function is closely tied to hydration status and metabolic load. Reduced food and fluid intake can increase the risk of dehydration, which may place additional strain on renal systems.
Individuals with underlying kidney concerns or rapid weight loss should consider how hydration and electrolyte balance impact overall safety.
This calculator evaluates these variables to identify potential renal stress scenarios.
Pancreas and Gallbladder (Biliary Risk Factors)
GLP-1 receptor agonists have been associated with changes in pancreatic activity and gallbladder function. These effects are influenced by weight loss rate, fat metabolism, and dietary composition.
Gallbladder issues may be linked to bile flow changes during rapid fat loss, while pancreatic stress may vary depending on individual susceptibility.
This tool highlights scenarios where these risks may be elevated.
Diabetes, Insulin Sensitivity, and Glucose Control
GLP-1 compounds are closely tied to glucose regulation. Individuals with diabetes or insulin resistance may experience different responses compared to those using GLP-1 for weight management alone.
Blood sugar stability, insulin sensitivity, and metabolic efficiency all contribute to risk and outcome variability.
This calculator integrates these inputs to reflect real metabolic conditions.
Weight, Obesity, and Metabolic Starting Point
Baseline body composition plays a significant role in determining both outcomes and risk. Individuals with obesity may experience more pronounced metabolic shifts, while those with lower body fat may encounter different tolerance thresholds.
Weight loss rate, caloric intake, and metabolic adaptation all influence the body’s response.
This tool uses weight-related inputs to contextualize these dynamics.
Nutrition Quality and Food Intake Patterns
Reduced appetite does not automatically equal improved nutrition. Poor dietary quality during GLP-1 use can lead to deficiencies, fatigue, and reduced recovery capacity.
Macronutrient balance, calorie intake, and food quality all influence outcomes.
This calculator evaluates dietary patterns as part of the overall risk profile.
Lifestyle, Exercise, and Behavior
Lifestyle factors such as exercise intensity, daily activity, and overall behavior patterns can influence how the body responds to GLP-1 compounds. While these are not direct inputs in this calculator, they play a role in how results should be interpreted, particularly during periods of rapid weight loss or reduced caloric intake.
Special Populations and Risk Modifiers
Certain populations may require additional consideration when evaluating GLP-1 risk. These include:
- Women (including pregnancy and postpartum considerations)
- Older adults
- Individuals with complex medical histories
Risk is not uniform across populations, and individual context matters.
Lifestyle, Exercise, and Behavior
Lifestyle variables significantly influence how GLP-1 compounds perform in real-world scenarios. Exercise intensity, daily activity levels, and behavioral consistency all impact metabolic outcomes, particularly during periods of reduced caloric intake.
While this calculator focuses on measurable clinical and metabolic inputs, these lifestyle factors should be considered when interpreting your results, as they can influence overall physiological stress and recovery capacity.
How the Risk Score Works
The output of this calculator is not a diagnosis. It is a structured way to evaluate how different variables interact.
Higher scores indicate a greater concentration of overlapping risk factors, while lower scores suggest fewer compounding variables.
This tool is designed to support more informed decision-making by organizing complex inputs into a usable framework.
The calculator generates a numerical score from 0 to 100, placing you into one of four risk tiers:
- Low (0–24): Routine monitoring is generally sufficient. Standard follow-up protocols apply.
- Moderate (25–44): Enhanced surveillance recommended. Consider more frequent check-ins during the initial treatment phase.
- High (45–64): Gastrointestinal consultation may be warranted before or during therapy initiation.
- Very High (65–100): Specialist evaluation is strongly recommended before proceeding with GLP-1 therapy.
Scores are derived from relative risk data published in randomized controlled trials, meta-analyses of 76 RCTs, and real-world pharmacovigilance reporting.
Who Should Use This Tool
This assessment is designed for individuals who are considering or currently using GLP-1 receptor agonists such as Wegovy, Ozempic, Mounjaro, or Zepbound. It is particularly relevant if you fall into any of these categories:
- You have been prescribed a GLP-1 medication and want to understand your side-effect risk profile
- You have a history of gallbladder problems, pancreatitis, or gastrointestinal disease
- You are pursuing rapid weight loss through GLP-1 therapy and want to monitor biliary risk
- You are managing Type 2 diabetes alongside weight management goals
- You want to evaluate how your diet type may influence your risk during treatment
GLP-1 Risk Assessment Calculator FAQ
What is a GLP-1 risk assessment calculator?
A GLP-1 risk assessment calculator is a screening tool that evaluates your likelihood of experiencing adverse effects from GLP-1 receptor agonist medications like semaglutide and tirzepatide. It analyzes personal health data, medication selection, dietary habits, and clinical history to generate a numerical risk score between 0 and 100, categorized into low, moderate, high, or very high risk tiers.
What risk factors does the GLP-1 assessment evaluate?
The calculator evaluates over 20 individual inputs across six categories: personal baseline data (height, weight, age, sex, BMI), GLP-1 medication selection and treatment duration, hard-stop contraindications (MTC history, MEN2, drug hypersensitivity), major cautions (pregnancy, pancreatitis, gallbladder disease, gastroparesis, kidney disease), weight loss velocity and dietary patterns, and ten weighted clinical risk factors including triglyceride levels, liver disease, tobacco use, and chronic kidney disease staging.
What are the side effects of GLP-1 medications?
GLP-1 receptor agonists carry several documented risks beyond common gastrointestinal symptoms. Biliary events including gallstones and cholecystitis occur at an elevated rate (RR 1.52 based on meta-analysis of 76 randomized controlled trials), with the risk being significantly higher when GLP-1 medications are used for weight loss (RR 2.29) compared to diabetes management (RR 1.27). Acute pancreatitis risk is also modestly elevated (RR 1.31). Additional concerns include delayed gastric emptying, potential interactions with oral contraceptives, and hypoglycemia risk when combined with insulin or sulfonylureas.
Who should not take GLP-1 medications?
GLP-1 receptor agonists are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma, those diagnosed with Multiple Endocrine Neoplasia syndrome type 2 (MEN2), and anyone with a known serious hypersensitivity to their selected GLP-1 agent. Major cautions apply to individuals who are pregnant or planning conception (discontinuation is required at least 2 months before planned conception for semaglutide and tirzepatide), those with active or prior pancreatitis, gallbladder disease, severe gastroparesis, or significant kidney impairment.
Does diet type affect GLP-1 side effect risk?
Yes. Dietary patterns influence biliary complication risk during GLP-1 therapy. Very low fat and low fat diets (under 20% of calories from fat) are associated with lower biliary risk. Balanced diets (20–35% fat) carry moderate risk. High fat diets exceeding 35% of calories from fat are associated with higher risk. Ketogenic diets carry moderate biliary risk primarily due to the rapid weight loss they often produce rather than the macronutrient ratio itself. Intermittent fasting also carries moderate risk because extended fasting windows reduce meal frequency, which decreases gallbladder contraction and may promote bile stasis.
How does weight loss speed affect GLP-1 risk?
Rapid weight loss is one of the strongest modifiable risk factors for gallbladder complications during GLP-1 therapy. Peak biliary event risk occurs between 6 and 12 months of treatment, coinciding with the most aggressive weight loss phase. Slower titration targeting less than 1 kilogram per week is associated with lower event rates. The calculator evaluates both your weekly weight loss rate and total weight loss percentage to factor this into your overall score.
What GLP-1 medications does the calculator include?
The calculator includes current FDA-approved GLP-1 receptor agonists and GLP-1/GIP dual agonists. Medication data is current as of March 2026 and includes recent approvals such as Wegovy HD 7.2 mg and Oral Wegovy 25 mg daily. Each agent is evaluated within the context of your selected indication (weight loss, Type 2 diabetes, or both) because risk profiles differ substantially between indications.
What do the GLP-1 risk score tiers mean?
The calculator assigns a score from 0 to 100 across four tiers. Low risk (0–24) indicates routine monitoring is generally appropriate with standard follow-up. Moderate risk (25–44) suggests enhanced surveillance with more frequent monitoring during early treatment. High risk (45–64) indicates gastrointestinal consultation should be considered before or during therapy. Very high risk (65–100) means specialist evaluation is strongly recommended before initiating GLP-1 treatment. These tiers are calibrated against safety data from randomized controlled trials and observational cohort studies.
Is GLP-1 therapy safe during pregnancy?
No. GLP-1 receptor agonists should not be used during pregnancy, while trying to conceive, or while breastfeeding. FDA labeling for semaglutide and tirzepatide requires discontinuation at least 2 months before planned conception. If pregnancy occurs during treatment, the medication should be stopped immediately and a physician consulted. The calculator flags this as a major caution and factors it into the risk assessment.
Can GLP-1 medications interact with other drugs?
GLP-1 receptor agonists have notable interactions with several medication classes. Combining them with insulin or sulfonylureas increases hypoglycemia risk and may require dose adjustment. GLP-1 medications can also reduce the effectiveness of oral hormonal contraceptives due to delayed gastric emptying — backup contraception should be considered during initiation and dose escalation. Individuals scheduled for surgery or procedures requiring anesthesia within 30 days should also disclose GLP-1 use, as delayed gastric emptying may increase aspiration risk.
What clinical evidence is the calculator based on?
The risk scoring model integrates data from multiple high-quality sources: a meta-analysis of 76 randomized controlled trials examining GLP-1 receptor agonists and biliary events, pooled analyses of acute pancreatitis incidence across GLP-1 trials, gastrointestinal adverse event data published in BMJ and JAMA, the FDA Adverse Event Reporting System (FAERS) database, and real-world pharmacovigilance data. Risk ratios and confidence intervals used in the scoring algorithm are drawn directly from these published datasets.
How is the GLP-1 risk calculator different from other screening tools?
Most GLP-1 resources focus on efficacy, how much weight you might lose or how much your A1C could drop. This calculator focuses exclusively on the risk side of the equation. It combines contraindication screening, medication-specific biliary risk ratios, dietary pattern analysis, weight loss velocity assessment, and ten weighted clinical risk factors into a single composite score. The tool also provides contextual explanations for each risk factor, citing the specific research behind each data point.
Important Disclaimer:
This peptide calculator is provided for research and educational purposes only and does not constitute medical advice, diagnosis, or treatment.
Assumption of Risk: Use of this calculator and any actions you take based on its results are at your own risk. We make no warranties regarding accuracy and are not liable for any damages, injuries, or losses arising from use of this tool.
Regulatory Notice: Many peptides are for research use only and may not be FDA-approved for human use. Verify the legal status in your jurisdiction.
Individual results vary. Never disregard professional medical advice or delay seeking it because of information on this website. In case of emergency or adverse reaction, seek immediate medical attention.